Antineoplastons (ANP) are peptides and amino acid derivatives, discovered by Dr. S. Burzynski, M.D., Ph.D. in 1967.

Dr. Burzynski first identified naturally occurring peptides in the human body that control cancer growth. He observed that cancer patients typically had deficiency of certain peptides in their blood as compared to healthy individuals.

According to Dr. Burzynski, Antineoplastons are components of a biochemical defense system that controls cancer without destroying normal cells.

Chemically, the Antineoplastons include peptides, amino acid derivatives and organic acids. They occur naturally in blood and urine and they are reproduced synthetically for medicinal use.

The name of Antineoplastons comes from their functions in controlling neoplastic, or cancerous, cells (anti-neoplastic cells agents).

Antineoplastons act as molecular switches, which turn off life processes in abnormal cells and force them to die through apoptosis (programmed death of a cell). While they trigger the death of cancer cells, they do not inhibit normal cell growth. They specifically target cancer cells without harming healthy cells.

It is generally known that the cancerous process results from increased activity of oncogenes and decreased expression of tumor suppressor genes. Antineoplastons “turn on” tumor suppressor genes and “turn off” oncogenes restoring the proper balance in gene expression.

Genetic mechanisms of Antineoplastons ( PDF )
Chemical formulas of active ingredients of Antineoplastons ( PDF )

Antineoplaston Therapy is an experimental therapy offered at the Burzynski Clinic, currently available only within
clinical trials.

To find out more about the eligibility criteria for enrollment in clinical trials, please contact our Cancer Information Specialist.

The continuous research on Antineoplastons indicates few and reversible side effects in a small percentage of patients. These include excessive gas in the stomach, dehydration, slight skin rash, slightly increased blood pressure, chills, fever and changes in mineral concentration in blood.

The continuous research on Antineoplastons is conducted and supervised by a team of experienced and committed scientists at our Clinic and the Burzynski Research Institute.